Gland Pharma Ltd News

Fosun's sale of Gland Pharma to become India's biggest pharma deal: Report

With the acquisition, Gland pharma may also get access to global companies like AstraZeneca, Sanofi, Mylan, and Organon

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Gland Pharma enters into agreement to acquire Cenexi; stock slips 5%

The acquisition provides Gland Pharma access to leading know-how and development capabilities in sterile forms including for ophthalmic gel, needleless injectors and hormones, the company said

Gland Pharma plunges 13%, hits 52-week low on disappointing Q2 results

Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin contracted 150 bps to 33 per cent from 38 per cent in a year ago quarter.

Gland Pharma's Q2 net dips 20.14% to Rs 241.24 cr; India revenue down 42%

Gland Pharma Ltd on Wednesday reported a 20.14 per cent decline in consolidated net profit at Rs 241.24 crore for the second quarter ended September 30, on lower sales and higher expenses. The company had posted a consolidated net profit of Rs 302.08 crore in the same period last fiscal, Gland Pharma said in a regulatory filing. The consolidated revenue from operations during the period under review were at Rs 1,044.4 crore, as against Rs 1,080.47 crore in the year-ago period, it added. Total expenses were higher at Rs 785.95 crore, as compared to Rs 731 crore in the same period a year ago, the company said. Gland Pharma said revenue from its core markets of US, Europe, Canada and Australia grew by 3 per cent to Rs 747.5 crore in the second quarter, as against Rs 722.5 crore in the corresponding period last fiscal. However, India revenue was down 42 per cent at Rs 72.6 crore, as compared to Rs 125.8 crore in the year-ago quarter, while the same for the 'rest of the world' market w

Here's why Mehul Kothari recommends buying Gland Pharma, Indian Oil

According to the technical analyst from Anand Rathi, Gland Pharma can rally to Rs 2,350, while IOC can spurt to Rs 83.